CORT
Corcept Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CORT
Corcept Therapeutics Incorporated
A commercial-stage pharmaceutical company that develops drugs to treat psychiatric/metabolic disorders assoiated with a steroid hormone cortisol
149 Commonwealth Drive, Menlo Park, CA 94025
--
Corcept Therapeutics Incorporated was incorporated in Delaware on May 13, 1998. The company is a commercial stage company engaged in the discovery and development of drugs to treat serious endocrine, tumor, metabolic and neurological diseases by regulating the action of the hormone cortisol.
Earnings Call
Q1/2025
Estimate EPS0.14
Actual EPS0.17
Estimate Revenue177.93M
Actual Revenue157.20M
Corcept Therapeutics Q1 2025: Unpacking Key Contradictions on Korlym Demand, Relacorilant NDA, and Clinical Strategies
May 06,2025 07:34
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CORT has released its 2025 Q3 earnings. EPS was reported at 0.16, versus the expected 0.14, beating expectations. The chart below visualizes how CORT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CORT has released its 2025 Q3 earnings report, with revenue of 207.64M, reflecting a YoY change of 13.75%, and net profit of 19.67M, showing a YoY change of -58.34%. The Sankey diagram below clearly presents CORT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
